Dr. Parkash Gill of the USC Norris Comprehensive Cancer Center has announced that the new cancer fighting drug EPH-B4 has been submitted to the FDA for Phase I Clinical Trials and is available to qualifying mesothelioma patients. In the initial Phase I Trial EPH-B4 is available to newly diagnosed patients who have not undergone any conventional treatment options and to those patients who have exhausted all other treatment options such as surgery and chemotherapy. This is truly exciting as Dr. Gill has reported that EPH-B4 has shown great promise as a solo treatment or in conjunction with other drugs as Alimta, Cisplatin and Carboplatin.
Please use our FaceBook link to obtain your FREE copy of our eBook that teaches:
Ask Dr. Gill about your specific mesothelioma issues here: Ask Dr. Gill
In addition to the eBook found at our Facebook fan page, also learn more about clinical trials from these links:
The Mesothelioma Research Foundation of America is the proud recipient of a grant from the John S. Lyons Memorial Foundation, charitable branch of the San Diego Building Trades Councel, to help support clinical studies of Dr. Parkash Gill's protein known as EPH B4 as a mesothelioma cancer treatment option.
The Mesothelioma Research Foundation of America has a mission: fund research that will lead to the quickest cure for mesothelioma. Mesothelioma is a cancer of the lining of the lungs caused by asbestos exposure. This cancer disease had few treatment options until this Foundation and Dr. Parkash Gill's work created better treatment options. Today, the future looks more hopeful for additional improved treatment options available to those stricken by this cancer.
The Mesothelioma Research Foundation of America began funding research for a cure in 2001 with the opening of the Mesothelioma Laboratory at USC Norris Comprehensive Cancer Medical Center in Los Angeles under the supervision of Dr. Parkash Gill.
Dr. Gill is a board certified oncologist and hematologist who has received FDA approval from the U.S. Government to do Clinical Trials on a mesothelioma treatment drug called Veglin. We believe there is great promise and hope in Veglin and the Mesothelioma Research Foundation of America has funded 100% of Dr. Gill's research.
Veglin proved successful in Phase I and Phase II clinical trials. Many are very hopeful for the possibilities of a more effective cancer treatment compared to what presently is available for mesothelioma victims. We are currently waiting for further FDA approval to begin Veglin as soon as possible.
For questions related to the foundation and to make contributions please contact:
(800) 909-Meso (6376)
5716 Corsa Avenue, Suite 203
Westlake Village, CA 91362
For more information and other questions contact:
©2012 Mesothelioma Research Foundation Of America